Table 2.

Overlap of published genome-wide association study single nucleotide polymorphisms for autoimmune diseases with those for dermatomyositis^*

Gene Name	SNP Marker	Original SNP/LD	Chr: Position	OR (CI)	P	FDR	SNP Disease Source [ref]
PLCL1	rs7572733	rs6738825/0.979	2: 198929806	0.80 (0.72–0.88)	6.18E-06	0.00089	SLE [17]
PLCL1	rs1518364	rs6738825/0.958	2: 198809975	1.22 (1.11–1.35)	5.11E-05	0.0037	SLE [17]
PLCL1	rs938929	rs6738825/0.958	2: 198780860	1.22 (1.10–1.34)	0.00008322	0.0030	SLE [17]
BLK	rs2736340		8: 11343973	1.25 (1.12–1.40)	0.0000653	0.0031	RA [14]
CCL21	rs2492358	rs951005/1.0	9: 34737828	0.77 (0.67–0.88)	0.0002093	0.0060	RA [14]
CCL21	rs951005		9: 34743681	0.77 (0.67–0.89)	0.000317	0.0076	RA [14]

^*Only SNPs with FDR < 0.05 are listed; SNP marker = directly genotyped single nucleotide polymorphism (SNP) by genome-wide association studies; Original SNP = original SNPs among 141 SNPs associated with autoimmune diseases, if not directly genotyped; LD = linkage disequilibrium in r² with the directly genotyped SNP on Illumina arrays; Chr = chromosome; Position = base pair in hg19/build37 coordinate; OR = odds ratio; CI = 95% confidence interval; P = fixed effect P value in meta-analysis; FDR = false discovery rate; SLE = systemic lupus erythematosus; RA = rheumatoid arthritis.